peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical terminates liquidity provider agreement

23 Mar 2011, 08:00
Regulatory information

The Hansa Medical Board of Directors has decided to end the agreement with Remium AB regarding the service as liquidity provider in Hansa Medicals’ share. The current liquidity provider agreement will expire on March 23, 2011 and a new liquidity provider has not been appointed.

 

 

Files

For further information, please contact:

Hansa Medical AB
Bo Håkansson, Chairman
Mobile: +46 705 98 57 22
E-mail: boh@farstorp.com

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.